Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Clinical trial NCT05430919 · COMPLETED
Trial details
- NCT number
- NCT05430919
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-15
- Primary completion
- 2023-07-31
- Enrollment
- 217
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.